Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 25-Valent Pneumococcal Conjugate Vaccine in Healthy PCV-Naïve Adults

Next Previous
Trial Profile

A Phase 2, Multicenter, Randomized, Active-Controlled, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 25-Valent Pneumococcal Conjugate Vaccine in Healthy PCV-Naïve Adults

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IVT-25 (Primary) ; Pneumococcal 20-valent conjugate vaccine
  • Indications Pneumococcal infections
  • Focus Adverse reactions
  • Sponsors Inventprise

Most Recent Events

  • 02 Jan 2024 According to an Inventprise media release, Dr. Joanne Langley is a principal investigator of this study.
  • 02 Jan 2024 According to an Inventprise media release, the study being conducted in collaboration with the international nonprofit organization PATH, Canadian Center for Vaccinology (Halifax), Vaccine Evaluation Center (British Columbia), Colchester Research Group (Nova Scotia) and Centre de recherche Saint-Louis (Quebec),
  • 02 Jan 2024 According to an Inventprise media release, the study is being conducted in four sites in Canada.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top